News

Article

Identifying Patients at High Risk of Myeloid Neoplasms After CAR T: Implications for Care, Surveillance

Author(s):

For chimeric antigen receptor T-cell therapies (CAR T) approved to treat B-cell lymphoproliferative disorders and multiple myeloma, more data are needed on the effects of posttreatment myeloid neoplasms to optimize patient counseling, risk stratification, and surveillance.

Although myeloid neoplasms (MNs) are a known potential adverse effect of chimeric antigen receptor (CAR) T-cell therapy—associated with severe neurotoxicity and survival of less than 1 year1,2—more data are needed on MNs post CAR T to optimize patient counseling, risk stratification, and surveillance among patients with B-cell lymphoproliferative disorders (LPDs) or multiple myeloma (MM), according to a new study.

Blood cancer treatment | Image credit: ployker-stock.adobe.com

Blood cancer treatment | Image credit: ployker-stock.adobe.com

Findings from this analysis of incidence rates and factors associated with MNs following CAR T were published online today in JAMA Oncology.3 All patients in this analysis had LPDs or MMs, received CAR T, and were treated for post–CAR T MNs at Mayo Clinic locations in Arizona, Florida, and Minnesota between June 1, 2016, and December 31, 2021. Patients with LPDs or MM (n = 20) were matched 6:1 to patients who also received CAR T but did not develop MNs (the control group; n = 120). Hematologic toxicity was evaluated via CAR-HEMATOTOX score (0-1, low; > 2, high4).

Overall, 20 patients—60% female patients, median (IQR) age, 67 (52-76) years—had developed MNs following CAR T infusion by a median 10 (5018) months. This was seen with a median follow-up of 14 (6-23) months. Measuring incidence rates of post–CAR T MNs at 1, 2, and 3 years after infusion, the investigators saw comparable rates of 4%, 6%, and 9%, respectively, between the patients treated for LPDs or MM.

Clonal hematopoiesis was seen in 64% of the patients who developed MNs, with TP53 and PPM1D being the primary genes involved.

Univariate analysis showed a higher risk of developing MNs if the patient was older, at 65 years or more vs younger than 65 years (HR, 4.99; 95% CI, 1.81-13.76; P = .002); had a low platelet count, at more than 140,000/mcL vs 140,000/mcL or less (HR, 3.69; 95% CI, 1.34-10.18; P = .01); and had a low hemoglobin level, at 9 g/dL or less vs more than 9 g/dL (HR, 2.96; 95% CI, 1.21-7.25; P = .02).

Four additional pairwise multivariate analyses were conducted to evaluate the effects of age 65 and older/hemoglobin level of 9 g/dL or less (Model A), 65 years and older/platelet count of 140,000/mcL or less (Model B), hemoglobin level of 9 g/dL or less/ platelet count of 140,000/mcL or less (Model C), and CAR-HEMATOTOX score of 2 or higher/age 65 and older (Model D).

Only Model B (65 years and older/platelet count of 140,000/mcL or less) was favored by concordance index (0.776), a tool that evaluates prediction model performance. Having 1 factor indicated intermediate risk of developing MNs (4 cases per 100 person-years) and having the 2 factors, high risk (27 cases per 100 person-years); 16% of the patients were considered high risk and 48%, low risk (P < .001). There were more than 80 years of follow-up with this model, and no post–CAR T MNs were seen among the low-risk patients (43%).

Limitations of these findings include that a direct link between CAR T and development of MNs was not possible because the authors noted that every patient had a history of prior cytotoxic therapy, the use of next-generation sequencing prior to CAR T is still considered an investigational method, and there was a lack of independent cohort validation.

“Furthermore, hazard ratios derived from controls reflect an enriched sample and are not generalizable,” they concluded. “Instead, incidence rates calculated from patients receiving commercial CAR T are informative. These observations require confirmation in larger multicenter or registry-based studies.”

References

  1. Saini NY, Swoboda DM, Greenbaum U, et al. Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma. Blood Cancer Discov. 2022;3(5):385-393. doi:10.1158/2643-3230.BCD-21-0177
  2. Alkhateeb HB, Mohty R, Greipp P, et al. Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma. Blood Cancer J. 2022;12(7):113. doi:10.1038/s41408-022-00707-4
  3. Gurney M, Baranwal A, Rosenthal A, et al. Features and factors associated with myeloid neoplasms after chimeric antigen receptor T-cell therapy. JAMA Oncol. Published online February 22, 2024. doi:10.1001/jamaoncol.2023.7182
  4. Larkin S, Surette E. The CFAR-HEMATOTOX model for CAR T-cell hematotoxicity in R/R LBCL. LymphomaHub. August 16, 2021. Accessed February 21, 2024. https://lymphomahub.com/medical-information/the-car-hematotox-model-for-car-t-cell-hematotoxicity-in-rr-lbcl

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Merrill H. Stewart, MD
Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center
EHA 2025 Congress Recap | Image Credit: Venngage
Ashley Yocum, PhD
Dr Matthew Matasar
Dr Xavier Leleu
Dr Marina Kremskayana
Dr Sundar Jagannath
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo